NEW YORK, May 5 (GenomeWeb News) – Bio-Rad reported yesterday a 3 percent increase in its first-quarter revenues to $308.3 million from $299.2 million during the year-ago period. Net income decreased 6.9 percent to $31.2 million from $33.5 million during the first quarter of 2005. Research and development grew 4.7 percent to $28.1 million from $26.8 million a year ago. Net sales from Bio-Rad’s Life Science segment were $144.8 million, up 0.5 percent from $144.1 million during the first quarter of 2005.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.